Related Experiment Video
Updated: Jul 9, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
CKD-MBD: impact on management of kidney disease
Hiroaki Ogata1, Fumihiko Koiwa2, Eriko Kinugasa3
1Department of Internal Medicine, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-Chuo, Tsuzuki, Yokohama, 224-8503, Japan. ogatah@med.showa-u.ac.jp.
Insights
Chronic kidney disease (CKD) mineral and bone disorder (CKD-MBD) significantly increases cardiovascular risks in dialysis patients. Novel treatments for CKD-MBD may improve outcomes and slow kidney disease progression.
Area of Science:
- Nephrology
- Endocrinology
- Cardiovascular Medicine
Background:
- Chronic kidney disease (CKD) is linked to bone and mineral metabolism abnormalities, termed CKD mineral and bone disorder (CKD-MBD).
- CKD-MBD is a major contributor to high cardiovascular disease (CVD) rates and mortality in end-stage kidney disease (ESKD) patients.
- Effective CKD-MBD management may reduce cardiovascular complications and potentially slow CKD progression.
Purpose of the Study:
- To review emerging therapeutic strategies for managing CKD-MBD.
- To highlight novel agents for improving mineral and bone health in CKD patients.
Main Methods:
- Literature review of recent advancements in CKD-MBD treatment.
- Focus on novel pharmacological agents and their clinical applications.
Main Results:
- New treatments for CKD-MBD are now available.
- These include active vitamin D analogues, phosphate binders free of calcium, and cinacalcet.
Conclusions:
- Novel therapeutic agents offer new options for managing CKD-MBD.
- Optimizing CKD-MBD treatment is crucial for reducing cardiovascular morbidity and mortality in ESKD.
- These strategies may also positively impact CKD progression.
Abstract:
Chronic kidney disease (CKD) causes various bone mineral disorders, which have recently been named CKD mineral and bone disorder (CKD-MBD). CKD-MBD is associated with extremely high cardiovascular disease (CVD) morbidity and mortality in the endstage kidney disease (ESKD) population. Thus, optimal management of CKD-MBD would lead to a reduction in cardiovascular morbidity and mortality in uremic patients. In addition, it has been suggested that the treatment of CKD-MBD has some favorable effects on the progression of CKD. Recently, novel therapeutic agents, including active vitamin D analogues, noncalcium-containing phosphate binders, and cinacalcet, have become clinically available. In this article, we review novel therapeutic strategies for CKD-MBD.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease I: Introduction
Acute Kidney Injury V: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations